Metabolic & Weight
Dulaglutide
LY2189265; Trulicity
GLP-1 receptor agonist
This Dulaglutide entry draws on 41 cited sources published 2009 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- GLP-1 receptor agonist
- Drug class
- Metabolic & Weight
- Structure
- GLP-1 analog + IgG4 Fc; ~60 kDa
- Route
- SC injection
- Half-life
- ~5 days
- Evidence tier
- FDA-Approved
- Availability
- Prescription
- Research depth
- 311 indexed citations →
Mechanism of action
GLP-1 receptor agonist fused to human IgG4 Fc
Reported areas of research
T2D glycemic control; modest weight loss; cardiovascular protection (REWIND)
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials)
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning
Compared with
Dulaglutide has published head-to-head comparisons with 8 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Dulaglutide in research literature?
Published peptide research reports the following dosing approach for Dulaglutide: 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials). This is a research reference, not a clinical recommendation.
How is Dulaglutide administered in research?
Dulaglutide is administered via the following routes in published studies: SC injection.
What is the reported half-life of Dulaglutide?
The reported half-life of Dulaglutide is ~5 days.
Is Dulaglutide FDA-approved?
Yes. Dulaglutide is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.
What level of evidence supports Dulaglutide?
The current evidence base for Dulaglutide is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Dulaglutide?
Known concerns reported in the literature for Dulaglutide include: Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning. Always consult a qualified clinician before any human use.
Is there anyone who should not use Dulaglutide?
Yes. The FDA label for TRULICITY lists formal contraindications for Dulaglutide: TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY. Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4, 5.1 ). Patients with a serious hypersensitivity reaction to dulaglutide or any of the product components ( 4, 5.4 ). This is the label's own wording, quoted rather than paraphrased. Always consult a qualified clinician before any human use.
How does Dulaglutide work?
The mechanism of action reported for Dulaglutide in the literature: GLP-1 receptor agonist fused to human IgG4 Fc.
What is Dulaglutide studied for?
Dulaglutide has been studied in the published literature for: T2D glycemic control; modest weight loss; cardiovascular protection (REWIND). These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Dulaglutide?
Dulaglutide is classified as: GLP-1 receptor agonist. Also known as: LY2189265; Trulicity.
Combinations to avoid
Dulaglutide appears in 1 flagged combination catalogued on PeptideHelper.org:
- GLP-1 agonist + insulin or sulfonylureas, High risk per peptide research literature.
Drug class
- GLP-1 peptides, see all peptides tagged GLP-1.
Research focus area
All peptides studied for Metabolic & Weight, ranked by evidence tier and regulatory status.
Primary sources
- FDA Trulicity (dulaglutide) prescribing information
- Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — placebo-controlled trial. Lancet 2019. PMID 31189511
- Dungan KM et al. Once-weekly dulaglutide added to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab 2016. PMID 26799540
- Zoungas S et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology 2026. PMID 42114520
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) [NCT06739122 PHASE3 RECRUITING]
- Katamine A et al. Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications. Journal of diabetes investigation 2026. PMID 42499272
- Aljulajil FA et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis. Cureus 2026. PMID 42495484
- Sajjad M et al. GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence. Multiple sclerosis and related disorders 2026. PMID 42470876
- Jerlhag E. GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies. Biological psychiatry 2026. PMID 42461204
- Lipska KJ et al. Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation. Annals of internal medicine 2026. PMID 42441965
- Mantz L et al. Weight Gain on Lorlatinib is Associated with Accumulation of Visceral Adipose Tissue. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2026. PMID 42419484
- Shevchouk O et al. Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents. Behavioural brain research 2026. PMID 41653988
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease [NCT07537088 PHASE4 NOT_YET_RECRUITING]
- Noguchi T et al. Hepatic portal venous gas in a patient with diabetes on GLP-1 receptor agonist and alpha-glucosidase inhibitor. JCEM case reports 2026. PMID 42093866
- Marusic S et al. Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes. International journal of clinical pharmacology and therapeutics 2026. PMID 42087771
- Xu J et al. Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics. Journal of the American Society for Mass Spectrometry 2026. PMID 42087717
- Le Y et al. Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis. Foot & ankle specialist 2026. PMID 42609010
- Ruotolo G et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, obesity & metabolism 2026. PMID 42608321
- Wang Y et al. Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice. European journal of pharmacology 2026. PMID 42607855
- Bahar F et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study. Diabetes, obesity & metabolism 2026. PMID 42802295
- Roach KA et al. Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk. Regulatory toxicology and pharmacology : RTP 2026. PMID 42800499
- Taipale H et al. Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024. Acta psychiatrica Scandinavica 2026. PMID 42324672
- Cai CX et al. Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study. Ophthalmology 2026. PMID 42229813
- Alvina et al. Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis. Digestive diseases and sciences 2026. PMID 42207410
- Sattar N et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes care 2026. PMID 41940793
- Briere DA et al. Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. Molecular metabolism 2026. PMID 42829171
- Nicholls SJ et al. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis. European journal of preventive cardiology 2026. PMID 42875024
- Wang X et al. Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2026. PMID 42867646
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes [NCT05478707 PHASE2 RECRUITING]
- Le D et al. Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis. Diabetes care 2026. PMID 42937520
- Massarotto FC et al. Oral Health-Related Adverse Events of GLP-1 Receptor Agonists. JDR clinical and translational research 2026. PMID 42935458
- Barbosa LM et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis. Heart rhythm 2026. PMID 42933519
- Acquarone E et al. Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model. Alzheimer's & dementia (New York, N. Y.) 2026. PMID 42959452
- Sićović K et al. GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways. British journal of pharmacology 2026. PMID 42950887
- Melamed B et al. Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance. Pharmacoepidemiology and drug safety 2026. PMID 42946127
- Chidiac G et al. Dulaglutide-associated interstitial granulomatous dermatitis: A case report. JAAD case reports 2026. PMID 42903917
- Adly AAM et al. Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA). Diabetologia 2026. PMID 42618811
- Lin CH et al. Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus. The journal of prevention of Alzheimer's disease 2026. PMID 42570467
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes [NCT07668336 PHASE3 RECRUITING]
- Silverbeck J et al. Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial. Diabetes, obesity & metabolism 2026. PMID 43003406
- GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications [NCT07932119 COMPLETED]
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…